Global Markets Direct’s, ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited - The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Biocon Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Biocon Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Biocon Limited’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Biocon Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Biocon Limited’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
Adult Malignant Glioma Therapeutics Market Report Overview Adult Malignant Glioma Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Adult Malignant Glioma Therapeutics market types and applications. It is a focused study...
Cryptococcosis Therapeutics Market Report Overview Cryptococcosis Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Cryptococcosis Therapeutics market types and applications. It is a focused study on Cryptococcosis Therapeutics...
Solid Tumor Therapeutics Market Report Overview Solid Tumor Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Solid Tumor Therapeutics market types and applications. It is a focused study on Solid Tumor Therapeutics market...
Xerostomia Therapeutics Market Report Overview Xerostomia Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Xerostomia Therapeutics market types and applications. It is a focused study on Xerostomia Therapeutics market space...
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...
Global Microbiome Therapeutics Market to Reach $3.9 Billion by 2030
Market Report Coverage - Microbiome Therapeutics
• By Disease Type: Gastrointestinal and Infectious Diseases and Other Diseases
• By Region: North America, Europe, Asia-Pacific, and Rest-of-the-World
Insulin Like Growth Factor I - Pipeline Review, H2 2020
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020
According to the recently published report ’Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020’; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.